文献速递血液透析通路

HeRO移植物并非总是成功:当代透析通路中的评估

HeRO's Don't Always Win: Evaluating HeRO Grafts in Contemporary Dialysis Access.
PubMed 文献 · Ann Vasc Surg · 2026-01-10

BACKGROUND: The introduction of the hemodialysis reliable outflow (HeRO) graft in 2009 presented an alternative upper extremity access for hemodialysis (HD) patients with failing access sites.…

要点

  • HeRO移植物置入后血液透析通路维护干预次数显著减少。
  • 置入后6个月和1年的一期通畅率分别为50%和47%。
  • 72%的患者需全身抗凝以维持HeRO移植物通畅。

核心结论

  • HeRO移植物可减少维持移植物功能所需的再干预次数,且通路并发症发生率相对较低。
  • 多数HeRO患者需要全身抗凝治疗。
  • HeRO置入后血液透析通路干预次数有统计学显著减少。

主要发现

  • HeRO置入前患者平均接受4.61±3.91次血液透析通路维护操作。
  • HeRO置入后患者平均接受1.94±1.77次血液透析通路维护操作。
  • HeRO置入后6个月和1年的一期通畅率分别为50%和47%。
  • HeRO置入后1年和5年的二期通畅率分别为80%和27%。
  • HeRO置入后最常见的并发症是移植物血栓形成。

关键数值与推荐

  • HeRO移植物流入道构建最常见为肱动脉至聚四氟乙烯(PTFE),占55%。
  • 其次为动静脉流出道静脉至PTFE,占33%;PTFE移植物至移植物,占11%。

临床怎么用

  • 对于血管通路耗竭的血液透析患者,HeRO移植物可作为选项,但需注意多数患者需全身抗凝并监测血栓风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The introduction of the hemodialysis reliable outflow (HeRO) graft in 2009 presented an alternative upper extremity access for hemodialysis (HD) patients with failing access sites. Despite initial enthusiasm, experience has revealed strengths and limitations of HeRO access. This study's objective is to assess the contemporary use of HeRO grafts at 2 tertiary care centers. METHODS: The operative logs for patients undergoing HD access procedures were retrospectively reviewed at 2 tertiary care sites between January 2012 and July 2024. Only patients that underwent placement of a HeRO graft were abstracted for analysis. The average patient age, HeRO graft indication, HeRO graft technical construct, use of post-HeRO systemic anticoagulation, and HD interventions pre-/post-HeRO access procedure were abstracted. All other patients who did not undergo a HeRO graft intervention were excluded. RESULTS: Eighteen patients with end-stage kidney disease were identified as having undergone placement of a HeRO graft. Prior to HeRO placement, patients underwent 4.61 ± 3.91 HD access maintenance procedures. The most common construct for HeRO graft inflow was brachial artery to polytetrafluoroethylene (PTFE), 55%, followed by arteriovenous outflow vein to PTFE, 33%, and PTFE graft to graft, 11%. After HeRO placement, patients underwent 1.94 ± 1.77 HD access maintenance procedures. The primary patency rates at 6 months and 1 year were 50% and 47%, while secondary patency at 1 and 5 years were 80% and 27%, respectively. The most common post-HERO complication was graft thrombosis. Ultimately, 72% of patients required systemic anticoagulation to maintain HeRO graft patency. CONCLUSION: This contemporary analysis of HeRO graft use indicates the value of HeRO access: a lower number of reinterventions to maintain graft function, and relatively low incidence of access complications. Anticoagulation was required in the majority of HeRO patients. There was a statistically significant reduction in the number of HD access interventions after HeRO placement.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Munro T, Shaw J, Ulloa JG, et al. HeRO's Don't Always Win: Evaluating HeRO Grafts in Contemporary Dialysis Access. Ann Vasc Surg. 2026. PMID: 41525983. doi:10.1016/j.avsg.2026.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。